ArticleBritish journal of cancer1992
Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.
Article in British journal of cancer, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Dysregulation of the annexin family protein family is associated with prostate cancer progression.The American journal of pathology · 2003Pooled it
- Review
- Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.Breast cancer research : BCR · 2019Article
- Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.International journal of molecular sciences · 2018Review
- Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer.BMC cancer · 2016Article
- Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis.Journal of translational medicine · 2016Review
- Annexin A2: its molecular regulation and cellular expression in cancer development.Disease markers · 2014Review
- Prognostic significance of annexin II expression in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- Three are better than one: plasminogen receptors as cancer theranostic targets.Experimental hematology & oncology · 2013Article
- Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis.Journal of cancer research and clinical oncology · 2013Article
- Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanisms.The Journal of biological chemistry · 2012Article
- Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells.Cell proliferation · 2012Article
- Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2012Article
- Homing of cancer cells to the bone.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
- Annexin II represents metastatic potential in clear-cell renal cell carcinoma.British journal of cancer · 2009Article
- Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.Journal of cellular biochemistry · 2008Article
- Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.Cancer treatment reviews · 2007Review
- Role of Annexin-II in GI cancers: interaction with gastrins/progastrins.Cancer letters · 2007Review
- Proteome characterization of a human urothelial cell line resistant to the bladder carcinogen 4-aminobiphenyl.Proteome science · 2007Article
- Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II.BMC biochemistry · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The doxorubicin-selected multidrug resistant small cell lung cancer cell line, H69AR, is cross-resistant to the Vinca alkaloids and epipodophyllotoxins, but does not overexpress P-glycoprotein, a 170 kDa plasma membrane efflux pump usually associated with this type of resistance. Monoclonal antibodies were raised against the H69AR cell line and one of these, MAb 3.186, recognises a peptide epitope on a 36 kDa phosphorylated protein that is membrane associated, but not presented on the external surface of H69AR cells (Mirski & Cole, 1991). In the present study, in vitro translation and molecular cloning techniques were used to determine the relative levels of mRNA corresponding to the 3.186 antigen. In addition, a cDNA clone containing an insert of approximately 1.4 kb was obtained by screening an H69AR cDNA library with 125I-MAb 3.186. Fragments of this cloned DNA hybridised to a single mRNA species of approximately 1.6 kb that was 5 to 6-fold elevated in H69AR cells. Partial DNA sequencing and restriction endonuclease mapping revealed identity of the cloned DNA with p36, a member of the annexin/lipocortin family of Ca2+ and phospholipid binding proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.